BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rigel Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Rigel Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05909397-9103@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Veppanu (Vepdegestrant): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letr
 ozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/vepdegestrant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-9103@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Veppanu (Vepdegestrant): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (V
 epdegestrant) When Given With Other Medicines in People With Advanced or M
 etastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vepdegestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5548127
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05308264-10823@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:R289: Phase 1/2 readout est. (NCT05308264)
DESCRIPTION:R289\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: Study of 
 R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/r289#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05308264
URL:https://assetmemo.bio/drug/r289#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161974-2857@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06161974)
DESCRIPTION:Olutasidenib\, phase 2\, Glioma.\nStudy: Study of Olutasidenib 
 and Temozolomide in HGG\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06161974
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9103@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Veppanu (Vepdegestrant): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumo
 rs\nEstimated primary completion: 27 August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vepdegestrant#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604064-2857@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07604064)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Clin
 ical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07604064
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
